Michal O.
- Country
- Poland
- Department
- NA
Research Overview
- Phase 3 Trial Comparing Efficacy, Safety, and Immunogenicity of Aflibercept (RBS-001) Versus Aflibercept in Neovascular Age-Related Macular Degeneration
- (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
- Evaluation of SB11 Pre-Filled Syringe Usability in Patients with Neovascular AMD, Macular Edema Secondary to RVO, or Myopic Choroidal Neovascularization
Data & Insights
Has run more than one trial at 9 of 120 partner sites.
Specializations
Ophthalmology Research
This investigator specializes in treating complex retinal disorders, with particular emphasis on macular conditions and their innovative therapeutic management.
- Retinal vein occlusion and associated macular edema
- Neovascular age-related macular degeneration (nAMD)
- Advanced retinal therapeutic approaches
The investigator focuses on evaluating novel treatment protocols for vision-threatening retinal conditions.
Vision Care Innovation
The research encompasses assessment of intravitreal therapeutics and their applications in maintaining and improving visual acuity in patients with retinal disorders.
- Comparative effectiveness of ocular medications
- Best-corrected visual acuity optimization
- Extended-interval treatment protocols
Work centers on developing optimal treatment regimens for various macular pathologies.
Therapeutic Expertise
The investigator specializes in retinal disease management with particular focus on advanced therapeutic interventions for chronic eye conditions.
- Evaluation of novel ophthalmic treatments
- Management of complex retinal pathologies
- Long-term vision preservation strategies
Research activities concentrate on establishing effective treatment protocols for macular disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.